Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137806 | 0.97 | HSD17B3 (0.45) | HSD17B3PTPN1PTPN11HSP90AB1KDM4E | |
| Zinc Ion SCHEMBL11170436 | 0.97 | HSD17B3 (0.45) | HSD17B3PTPN1PTPN11HSP90AB1KDM4E | |
| Water SCHEMBL8361961 | 0.95 | HSD17B3 (0.44) | HSD17B3PTPN1PTPN11HSP90AB1KDM4E | |
| Potassium Ion SCHEMBL761984 | 0.90 | TYR (0.53) | HSD17B3HSP90AB1KDM4EHTTMAPT | |
| Paraben SCHEMBL3515235 | 0.89 | CA1 (0.53) | HSD17B3PTPN1PTPN11HSP90AB1KDM4E | |
| Potassium Ion SCHEMBL1012149 | 0.87 | HSD17B1 (0.50) | HSD17B3HSP90AB1KDM4EHTTCA12 | |
| SCHEMBL5152452 | 0.87 | TYR (0.53) | HSD17B3HSP90AB1KDM4EHTTMAPT | |
| SCHEMBL2325181 | 0.87 | TYR (0.53) | HSP90AB1KDM4EHTTMAPTCA12 | |
| SCHEMBL344000 | 0.87 | TYR (0.53) | HSP90AB1KDM4EHTTMAPTCA12 | |
| Zinc Ion SCHEMBL11175859 | 0.84 | HSD17B1 (0.50) | HSD17B3HSP90AB1KDM4EHTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608929-A1 | BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT | LyondellBasell Advanced Polymers Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12338390-B2 | Bridging particle and fluid loss control agent | LYONDELLBASELL ADVANCED POLYMERS INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-20240228859-A9 | BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT | LYONDELLBASELL ADVANCED POLYMERS INC. (US) | 2024-07-11 | — | — | US | claimed |
| WO-2024091462-A1 | BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT | LYONDELLBASELL ADVANCED POLYMERS INC. (US) | 2024-05-02 | — | — | WO | claimed |
| US-20240132772-A1 | BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT | LYONDELLBASELL ADVANCED POLYMERS INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20230363380-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2023-11-16 | — | — | US | claimed |
| US-20220079145-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2022-03-17 | — | — | US | claimed |
| US-20180077925-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2018-03-22 | — | — | US | claimed |
| US-8933097-B2 | Fexofenadine suspension formulation | SANOFI-AVENTIS U.S. LLC (US) | 2015-01-13 | — | — | US | claimed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | claimed |
| EP-1965768-B1 | FEXOFENADINE SUSPENSION FORMULATION | SANOFI AVENTIS US LLC (US) | 2009-05-13 | — | — | EP | claimed |
| US-20080299211-A1 | FEXOFENADINE SUSPENSION FORMULATION | SANOFI-AVENTIS U.S. LLC. (US) | 2008-12-04 | — | — | US | claimed |
| EP-1965768-A2 | FEXOFENADINE SUSPENSION FORMULATION | Sanofi-Aventis U.S. LLC (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007070517-A2 | FEXOFENADINE SUSPENSION FORMULATION | SANOFI-AVENTIS U.S. LLC (US) | 2007-06-21 | — | — | WO | claimed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | claimed |
| EP-3592329-B1 | USE OF COMPATIBLE SOLUTES | SUSONITY Commercial GmbH (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | SYMRISE AG (DE) | 2026-02-12 | — | — | US | disclosed |
| WO-2001047476-A2 | ANTIPERSPIRANT COMPOSITION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001047488-A2 | ANTIPERSPIRANT COMPOSITION THAT CONTAINS A WATER-SOLUBLE ANTIPERSPIRANT ACTIVE AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2000026285-A1 | GEL COMPOSITIONS | PENRECO (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299211-A1 | FEXOFENADINE SUSPENSION FORMULATION | PEF1, SLC10A2, FLAD1 | HSD17B3 692/4885PTPN1 2922/4885PTPN11 2326/4885 |
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | TLR7, MYC, ERG28 | HSD17B3 3730/4885PTPN1 478/4885PTPN11 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.